Expert Review of Anti-Infective Therapy

Papers
(The TQCC of Expert Review of Anti-Infective Therapy is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Part 1: Understanding the role of Malassezia spp. in skin disorders: Malassezia yeasts as commensal or pathogenic organisms of human and a108
The efficacy and safety of complement C5a inhibitors for patients with severe COVID-19: a systematic review and meta-analysis91
Visceral leishmaniasis elimination in India: progress and the road ahead70
A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future64
Optic and peripheral neuropathy associated with short and prolonged administration of tedizolid: a review51
The efficacy and safety of ceftolozane-tazobactam in the treatment of GNB infections: a systematic review and meta-analysis of clinical studies48
Challenges in preserving antibiotic effectiveness: time for a novel approach43
Emerging issues on Staphylococcus aureus endocarditis and the role in therapy of daptomycin plus fosfomycin41
Neonatal ocular prophylaxis in the United States: is it still necessary?40
Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex40
The emergence of Japanese encephalitis as a public health concern in New South Wales Australia39
Preventing healthcare-related infections among older adults: a focus on cross-transmission of antibiotic-resistant bacteria36
Nontuberculous mycobacterial pulmonary disease and the potential role of SPR72035
Tackling antimicrobial resistance in sub-Saharan Africa: challenges and opportunities for implementing the new people-centered WHO guidelines35
Recent updates in treating carbapenem-resistant infections in patients with hematological malignancies30
Response to: ‘letter to the editor: “A multifaceted strategy is needed to limit the over-the-counter sale of antimicrobials “’29
Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China27
Tineas caused by hedgehogs due to Trichophyton erinacei an ascending agent of dermatophytosis27
All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies26
Treatment of vaginitis caused by non-albicans Candida species26
New and emerging roles for inhalational and direct antifungal drug delivery approaches for treatment of invasive fungal infections25
Decoding drug resistance in Mycobacterium tuberculosis complex: genetic insights and future challenges24
Hypoalbuminemia as a predictor of severe dengue: a systematic review and meta-analysis24
Reemergence of monkeypox: prevention and management23
The ongoing challenge of prevention of pertussis in infants: what’s new in 2024?23
Identifying predictors of treatment failure with community-acquired pneumonia: an update23
Can inhaled antifungals provide a viable solution for treatment-refractory pulmonary fungal infections?23
Advances and controversies in the diagnosis and management of neurocysticercosis: a clinical perspective22
Direct or early Discharge of Acute Bacterial Skin and Skin Structure Infection patients from the Emergency Department/Unit: place in therapy of dalbavancin22
Diagnostic and clinical management of Candida auris infections in immunocompromised patients21
Iatrogenic factors of Helicobacter pylori eradication failure: lessons from the frontline21
Phage- and enzybiotic-coated urinary catheters to prevent recurrent multidrug-resistant bacterial infections19
Effectiveness of recently-approved oral antiviral medications on the outcome of patients with mild-to-moderate COVID-19 and pre–existing chronic obstructive pulmonary diseases18
Infliximab as a potential treatment for COVID-1918
Predicting the limit to ceftriaxone’s use in gonorrhea treatment: impending resistance and logistical challenges18
Anti-inflammatory and immunomodulatory effects of mesenchymal stem cell therapy on parasitic drug resistance17
Healthcare professionals’ understanding and perception of drug-related issues linked to off-label pharmacological medications used for COVID-1917
Real-world effectiveness and tolerability of post solid organ transplant patients with CMV switching from valganciclovir treatment to maribavir: analysis using lab-linked claims data in the United Sta17
Analysis of bacterial spectrum and construction of a predictive model for postoperative sepsis in patients with upper urinary calculi and positive urinary cultures17
Diagnostic and management strategies for chronic hepatitis E infection17
Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases17
Understanding host responses to equine encephalitis virus infection: implications for therapeutic development16
Correction16
Updates on Candida albicans infections: pathogenesis, resistance, and emerging nanopharmaceutical strategies16
Theranostic nanomaterials for scalp and hair fungal infections: advancing diagnosis and treatment amidst challenges16
In vitro and in vivo activity of meropenem+avibactam against MBL-producing carbapenem-resistant Klebsiella pneumoniae15
Nintedanib: a review of the properties, function, and usefulness to minimize COVID-19-induced lung injury15
Perceptions and preparedness of senior medical students about antimicrobial stewardship programs: are we providing adequate training to future prescribers?15
The opportunities and challenges of epigenetic approaches to manage herpes simplex infections15
Risk of HIV viral rebound after SARS-CoV-2 infection among people living with HIV on antiretroviral therapy: a retrospective matched cohort study15
Statement of Retraction15
Oteseconazole: a long-awaited diversification of the antifungal arsenal to manage recurrent vulvovaginal candidiasis (RVVC)14
Selling antibiotics without prescriptions among community pharmacies and drug outlets: a simulated client study from Ghana14
Challenges, risks, and opportunities of antiretroviral drugs in women of reproductive potential14
Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed Metallo-β-lactamase production: a systemat14
How SARS-CoV-2 dodges immune surveillance and facilitates infection: an analytical review14
The serological dilemma: rethinking syphilis treatment evaluation14
Low-risk penicillin allergy delabeling: a scoping review of direct oral challenge practice, implementation, and multi-disciplinary approaches13
Diagnosing fungal infections in clinical practice: a narrative review13
Interrupting HIV transmission networks: how can we design and implement timely and effective interventions?12
Predictors and patterns of empirical antibiotic therapy and associated outcomes in COVID-19 patients: a retrospective study in a tertiary care facility in South India12
Exploring thresholds and interaction effects among antibiotic usage, covariates, and their effect on antibiotic resistance using an extended-spectrum β-Lactamase–producing Klebsiella pneumoniae12
The evolving debate around screening for Chlamydia trachomatis12
New advances in management and treatment of multidrug-resistant Klebsiella pneumoniae12
Monoclonal antibodies for the treatment of COVID-19 infection in children12
Clinical utility of procalcitonin in implementation of procalcitonin-guided antibiotic stewardship in the South-East Asia and India: evidence and consensus-based recommendations12
Interaction of zincite, alpha-terpineol, geranyl acetate, linalool, myrcenol, terpinolene, and thymol with virulence factors of Escherichia coli, Mycobacterium tuberculosis, Pseudomonas11
Challenges associated with pertussis detection, monitoring, and vaccination in adults11
How can we tackle the overuse of antibiotics in low- and middle-income countries?11
Investigating forthcoming strategies to tackle deadly superbugs: current status and future vision11
An overview of potential combination therapies with ceftriaxone as a treatment for gonorrhoea11
Immunomodulatory markers and therapies for the management of infant respiratory syncytial virus infection11
Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review10
Evaluation of Namibia’s antiretroviral therapy guidelines’ recommendations for switching from first-line to second-line, using predictors of first-line treatment failure: an exploratory study10
Phage therapy: resurrecting a historical solution for the contemporary challenge of rising antibiotic resistance in Latin America10
A 96-week efficacy and safety of BIC/FTC/TAF in ART-naïve HIV-1 infected patients in China10
Clinical outcomes, virological efficacy and safety of nitazoxanide in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials10
Tocilizumab for the treatment of COVID-1910
Monotherapy versus combination for the treatment of Stenotrophomonas maltophilia: a multicenter cohort study10
The evolving scenario of HCV-related mixed cryoglobulinemia and B-cell lymphoma in the era of direct-acting antivirals10
Practices, Knowledge, and Attitudes of Nephrologists Towards Prescribing and Monitoring Vancomycin at Dialysis Centers10
How do we best manage Clostridioides difficle infections in the elderly?10
Gram-positive infections in special populations. Expert view on the role of dalbavancin9
Women trailblazers shaping the global future of antimicrobial stewardship and antimicrobial resistance9
New insights into the treatment of acute otitis media9
Real-life effectiveness of antiviral therapy for HCV infection with pangenotypic regimens in HIV coinfected patients9
Could Herpesviridae be the cause of severe acute hepatitis of unknown origin in children?9
Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis9
Understanding mechanisms of virulence in MRSA: implications for antivirulence treatment strategies9
Update on actinomycetoma treatment: linezolid in the treatment of actinomycetomas due to Nocardia spp and Actinomadura madurae resistant t9
Artificial intelligence and prescription of antibiotic therapy: present and future9
Now that griseofulvin is not available, what to do with tinea capitis treatments?9
Contemporary pharmacologic treatments of MRSA for hospitalized adults: rationale for vancomycin versus non-vancomycin therapies as first line agents9
Clinical efficacy of probiotics in the treatment of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials9
Comparison of clinical outcomes of antibiotics used for Staphylococcus aureus bacteremia in pediatric patients9
Vitamin D attenuates biofilm-associated infections via immunomodulation and cathelicidin expression: a narrative review9
Past, present, and future perspectives on aztreonam and avibactam8
Global importance of new treatment strategies to efforts to control hepatitis B virus8
RETRACTED ARTICLE: Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial8
Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options8
Metallo-beta-lactamases: mechanisms, treatment challenges, and future prospects8
An update on newer antifungals8
Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-198
Public knowledge of antibiotics, self-medication, and household disposal practices in Jordan8
Efficacy and safety of eravacycline (ERV) in treating infections caused by Gram-negative pathogens: a systematic review and meta-analysis8
Containment strategies for COVID-19 in India: lessons from the second wave8
Synergistic effect of eravacycline combined with fluconazole against resistant Candida albicans in vitro and in vivo8
0.10820078849792